Copyright
©The Author(s) 2021.
World J Stem Cells. Jul 26, 2021; 13(7): 670-684
Published online Jul 26, 2021. doi: 10.4252/wjsc.v13.i7.670
Published online Jul 26, 2021. doi: 10.4252/wjsc.v13.i7.670
Table 2 DNA methyltransferase inhibitors in clinical trial for brain cancer treatment
Compound | Class | Target | Conditions | Phase of clinical trial | Study title |
5-Azacytidine | DNMTi | Pan-DNMT | Brain tumor recurrent | Early Phase 1 | Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Ependymoma |
Azacitidine | DNMTi | Pan-DNMT | GBM multiformeOther | Phase 1 | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies |
5-Azacytidine | DNMTi | Pan-DNMT | Recurrent childhood CNS tumor | Phase 1 | Treatment of Children With Recurrent Refractory Brain/Solid Tumors and Recurrent Ependymoma |
Ependymoma, recurrent childhood | |||||
Childhood solid tumor |
- Citation: Abballe L, Miele E. Epigenetic modulators for brain cancer stem cells: Implications for anticancer treatment. World J Stem Cells 2021; 13(7): 670-684
- URL: https://www.wjgnet.com/1948-0210/full/v13/i7/670.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v13.i7.670